Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Treatment for Ovulation Induction in Nonobese Anovulatory Women with Polycystic Ovary Syndrome

  Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Treatment for Ovulation Induction in Nonobese Anovulatory Women with Polycystic Ovary Syndrome JCEM ปี 2547 Author: Stefano Palomba, Francesco Orio, Jr., Angela Falbo, Francesco Manguso, Tiziana Russo, Teresa Cascella, Achille Tolino, Enrico Carmina, Annamaria Colao and Fulvio Zullo Department of Obstetrics and Gynecology (S.P., A.F., T.R., F.Z.), University “Magna Graecia” of Catanzaro, 80131 Naples, Italy; Departments of Molecular and Clinical Endocrinology and Oncology (F.O., T.C., A.C.), Internal Medicine (F.M.), and Obstetrics and Gynecology (A.T.), University “Federico II” of Naples, 80138 Naples, Italy; and Department of Endocrinology (E.C.), University of Palermo, 90128 Palermo, Italy Context: Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients. Objective: The goal of this study was to compare the effectiveness […]

Diabetes Care :: May 2007, Volume 30, Number 5

  Diabetes Care :: May 2007, Volume 30, Number 5 May 2007, Volume 30, Number 5 ปี 2548 Contents: May 2007, Volume 30, Number 5   [Index by Author]  [Cover Caption]  Original Articles       Clinical Care/Education/Nutrition       Epidemiology/Health Services/Psychosocial Research       Emerging Treatments and Technologies       Pathophysiology/Complications       Cardiovascular and Metabolic Risk    Brief Reports       Clinical Care/Education/Nutrition       Epidemiology/Health Services/Psychosocial Research       Pathophysiology/Complications       Cardiovascular and Metabolic Risk    Reviews/Commentaries/ADA Statements       Review Articles       Perspectives on the News

The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes

The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes Diabetes Care 28:2261-2266, 2005 ปี 2548   Reviews/Commentaries/ADA Statements Meta-Analysis. ABSTRACT OBJECTIVE—Angiotensin II has been shown to increase hepatic glucose production and decrease insulin sensitivity. Patients who utilize either an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-onset type 2 diabetes.  RESEARCH DESIGN AND METHODS—Three reviewers conducted a systematic literature search of Medline, EMBASE, CINAHL, and the Cochrane Library (1966 to present) to extract a consensus of trial data involving an ACEI or ARB with an end point of new-onset type 2 diabetes. Studies were included if they were randomized controlled trials verses placebo/routine therapy. A random-effects model was utilized. Subgroup and sensitivity analyses were conducted.  RESULTS—Eleven trials were identified, including 66,608 patients. An ACEI or ARB prevented new-onset type 2 diabetes (odds ratio 0.78 [95% CI 0.73–0.83]). The influence of either an ACEI (six trials) or […]

Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy

Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy Diabetes Care 28:2106-2112, 2005 ปี 2548   Authors: Kasper Rossing, MD1, Katrine J. Schjoedt, MD1, Ulla M. Smidt1, Frans Boomsma, PHD2 and Hans-Henrik Parving, MD, DMSC1,3 OBJECTIVES: –  The objective of this study was to evaluate the safety and short-term effect of adding spironolactone to conventional antihypertensive treatment including diuretics and maximally recommended doses of an ACE inhibitor or an angiotensin II receptor blocker (ARB) on albuminuria and blood pressure in type 2 diabeticpatients with nephropathy. RESEARCH DESIGN AND METHODS—Twenty-one type 2 diabetic patients with nephropathy were enrolled in a randomized, double-masked, cross-over study. Patients were treated in random order with spironolactone 25 mg once daily and matched placebo for 8 weeks, respectively, in addition to ongoing antihypertensive treatment including diuretics and maximally recommended doses of an ACE inhibitor and/or an ARB. At the end of each treatment […]

Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and Induces Their Remission in Morbid Obesity

Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and Induces Their Remission in Morbid Obesity Diabetes Care. 2005;28:2703-2709 ปี 2548 Authors: Antonio E. Pontiroli, MD1,2, Franco Folli, MD, PHD3, Michele Paganelli, MD4, Giancarlo Micheletto, MD5,Pierluigi Pizzocri, MD1,2, Paola Vedani, MD3, Francesca Luisi, PHD3, Lucia Perego, PHD3, Alberto Morabito, PHD1 andSanto Bressani Doldi, MD5 1 Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Milano, Milan, Italy 2 Divisione di Medicina 2, Ospedale San Paolo, Milan, Italy 3 Divisione di Medicina, Ospedale San Raffaele, Milan, Italy 4 Divisione di Chirurgia, Ospedale San Raffaele, Milan, Italy 5 Dipartimento di Scienze Chirurgiche, Istituto Clinico Sant Ambrogio, Milan, Italy OBJECTIVE—Lifestyle modifications and pharmacological interventions can prevent type 2 diabetes in obese subjects with impaired glucose tolerance. The aim of this study was to compare laparoscopic adjustable gastric banding (LAGB) and conventional diet (No-LAGB) in the prevention (primary intervention study; 56 vs. […]